IN VITRO AND IN VIVO EFFICACY OF TRASTUZUMAB DERUXTECAN (T-DXD) IN EPITHELIAL OVARIAN CANCER WITH HER2/NEU OVEREXPRESSION

被引：0

作者：

Mutlu, Levent ^{[1
]}

Manavella, Diego ^{[1
]}

Bellone, Stefania ^{[1
]}

Santin, Alessandro ^{[1
]}

机构：

[1] Yale Univ, Obstet Gynecol & Reprod Sci, New Haven, CT USA

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2022年 / 32卷

关键词：

D O I：

10.1136/ijgc-2022-igcs.106

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

EP015/#546

引用

页码：A54 / A54

页数：1

共 50 条

[31] T-DXd Demonstrates Real-World Efficacy in Advanced Breast Cancer With Dynamic HER2 EXPression
Antino, Tar
AMERICAN JOURNAL OF MANAGED CARE, 2024, 30 (02):
[32] Real world data on Trastuzumab Deruxtecan (T-DXd) induced Interstitial Lung disease (ILD) in HER2 positive metastatic breast cancer patients at the Kent Oncology Centre
Mohammed, S.
Moss, C.
Harper-Wynne, C.
CLINICAL ONCOLOGY, 2025, 38
[33] Population pharmacokinetics of trastuzumab deruxtecan (T-DXd) in subjects with HER2-mutant and HER2-overexpressing non-small cell lung cancer (NSCLC)
Khatri, Amit
Cobbina, Enoch
Cheng, Shen
Abutarif, Malaz
Garimella, Tushar
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[34] Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression
Menderes, Gulden
Bonazzoli, Elena
Bellone, Stefania
Altwerger, Gary
Black, Jonathan D.
Dugan, Katherine
Pettinella, Francesca
Masserdotti, Alice
Riccio, Francesco
Bianchi, Anna
Zammataro, Luca
de Haydu, Christopher
Buza, Natalia
Hui, Pei
Wong, Serena
Huang, Gloria S.
Litkouhi, Babak
Ratner, Elena
Silasi, Dan-Arin
Azodi, Masoud
Schwartz, Peter E.
Santin, Alessandro D.
GYNECOLOGIC ONCOLOGY, 2017, 147 (01) : 145 - 152
[35] Durable clinical and radiographic responses in a series of patients with HER2+Breast Cancer (BC) Leptomeningeal Disease (LMD) treated with trastuzumab deruxtecan (T-DXd).
Alder, Laura
Trapani, Dario
Van Swearingen, Amanda
Khasraw, Mustafa
Anders, Carey
Lin, Nancy
Sammons, Sarah
CANCER RESEARCH, 2022, 82 (12)
[36] HER2 persistence after treatment with T-DXd in breast and gastrointestinal cancers
Drago, Joshua Z.
Pareja, Fresia
Jhaveri, Komal L.
Walsh, Elaine M.
Ku, Geoffrey Yuyat
Maron, Steven Brad
Janjigian, Yelena Y.
Robson, Mark E.
Reis-Filho, Jorge S.
Modi, Shanu
Razavi, Pedram
Chandarlapaty, Sarat
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[37] Valemetostat and trastuzumab deruxtecan (T-DXd) in previously treated advanced or metastatic human epidermal growth factor receptor 2 (HER2)-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma
Shitara, K.
Enzinger, P. C.
Mohapatra, A. S.
Janjigian, Y. Y.
ANNALS OF ONCOLOGY, 2024, 35 : S200 - S200
[38] Trastuzumab deruxtecan (T-DXd) in patients with HER2+metastatic breast cancer with brain metastases: A subgroup analysis of the DESTINY-Breast01 trial.
Jerusalem, Guy Heinrich Maria
Park, Yeon Hee
Yamashita, Toshinari
Hurvitz, Sara A.
Modi, Shanu
Andre, Fabrice
Krop, Ian E.
Gonzalez, Xavier
Hall, Peter S.
You, Benoit
Saura, Cristina
Kim, Sung-Bae
Osborne, Cynthia R. C.
Sagara, Yasuaki
Tokunaga, Eriko
Liu, Yali
Cathcart, Jillian
Lee, Caleb C.
Perrin, Christophe
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[39] Uncovering Bystander Killing Mechanisms of Trastuzumab Deruxtecan (T-DXd): Effective Extracellular Payload Release via Cathepsin L in HER2-low Breast Cancer
Tsao, Li-Chung
Wang, John S.
Ragusa, Joey
Liu, Bushangqing
McBane, Jason
Spasojevic, Ivan
Fan, Ping
Trotter, Timothy N.
Lyerly, Herbert Kim
Hartman, Zachary C.
CANCER IMMUNOLOGY RESEARCH, 2024, 12 (10)
[40] Trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-expressing salivary duct carcinoma: Subgroup analysis of two phase 1 studies.
Bando, Hideaki
Kinoshita, Ichiro
Modi, Shanu
Tsurutani, Junji
Bang, Yung-Jue
Iwata, Hiroji
Sato, Yuta
Nakatani, Shunsuke
Lee, Caleb C.
Sugihara, Masahiro
Okuda, Yasuyuki
Takahashi, Shunji
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 5 →